Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (&gt;/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Brief Summary: This randomized phase III trial studies rituximab with bendamustine hydrochloride or ibrutinib to see how well they work compared to ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether rituximab with bendamustine hydrochloride may work better than rituximab and ibrutinib or ibrutinib alone in treating chronic lymphocytic leukemia.


Options:
A: Arm Label: Arm I (rituximab, bendamustine hydrochloride); Type: ACTIVE_COMPARATOR; Interventions: Drug: Bendamustine Hydrochloride, Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspiration, Procedure: Bone Marrow Biopsy, Procedure: Computed Tomography, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Biological: Rituximab | Arm Label: Arm II (ibrutinib); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspiration, Procedure: Bone Marrow Biopsy, Procedure: Computed Tomography, Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment | Arm Label: Arm III (ibrutinib, rituximab); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspiration, Procedure: Bone Marrow Biopsy, Procedure: Computed Tomography, Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Biological: Rituximab | Intervention Type: DRUG; Name: Bendamustine Hydrochloride; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride) | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: PROCEDURE; Name: Bone Marrow Aspiration; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: PROCEDURE; Name: Bone Marrow Biopsy; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm II (ibrutinib), Arm III (ibrutinib, rituximab) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Arm I (rituximab, bendamustine hydrochloride), Arm III (ibrutinib, rituximab)
B: Arm Label: Arm A (ibrutinib, rituximab); Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Arm Label: Arm B (rituximab, fludarabine phosphate, cyclophosphamide); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm A (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Pharmacogenomic Study; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide)
C: Arm Label: Cohort 1: Bendamustine + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Cohort 1: Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 1a (China only): Bendamustine + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab | Arm Label: Cohort 1a (China only): Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 2: Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib | Arm Label: Cohort 3: Venetoclax + Zanubrutinib; Type: EXPERIMENTAL; Interventions: Drug: Zanubrutinib, Drug: Venetoclax | Intervention Type: DRUG; Name: Zanubrutinib; Assigned to Arm(s): Cohort 1: Zanubrutinib, Cohort 1a (China only): Zanubrutinib, Cohort 2: Zanubrutinib, Cohort 3: Venetoclax + Zanubrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Cohort 1: Bendamustine + Rituximab, Cohort 1a (China only): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Cohort 1: Bendamustine + Rituximab, Cohort 1a (China only): Bendamustine + Rituximab | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Cohort 3: Venetoclax + Zanubrutinib
D: Arm Label: Treatment Arm A: Ibrutinib and Venetoclax (I+VEN); Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Venetoclax, Drug: Ibrutinib (as Subsequent Therapy) | Arm Label: Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb); Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorambucil, Drug: Obinutuzumab, Drug: Ibrutinib (as Subsequent Therapy) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN) | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN) | Intervention Type: DRUG; Name: Chlorambucil; Assigned to Arm(s): Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb) | Intervention Type: DRUG; Name: Obinutuzumab; Assigned to Arm(s): Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb) | Intervention Type: DRUG; Name: Ibrutinib (as Subsequent Therapy); Assigned to Arm(s): Treatment Arm A: Ibrutinib and Venetoclax (I+VEN), Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)

Answer: A